Citations

Clear

400 citation(s) found for "Berry, DA".

Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104
Archer, Laura, Kornblith, Alice B., Grenier, Debjani, Perez, Edith A., Wolff, Antonio C. , Kastrissios, Helen , Berry, Donald A. , Hudis, Clifford A. , Muss, Hyman B. , Partridge, Ann H. , Gralow, Julie R. , Perez, Edith A. , Wang, Xiaofei , Winer, Eric P. , Wolff, Antonio C

Mayo Clinic

Journal of Clinical Oncology | April 6, 2010 | Volume: 28 | Issue: 14 | Pages: 2418-2422

10.1200/jco.2009.26.4671 | PMID 20368559 Get It

Purpose Patient adherence is critical in evaluating the effectiveness of an oral therapy. We sought to measure adherence among women randomly assigned to capecitabine in a preplanned substudy of a multicenter clinical trial. Patients and Methods Cancer and Leukemia Group B study CALGB 49907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with early-stage breast cancer. We used microelectronic monitoring system (MEMS) caps on participants' capecitabine bottles to record pill bottle openings. Capecitabine was given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles. Adherence was calculated as the number of doses taken divided by doses expected, taking into account toxicity-related dosing changes. A participant was defined as adherent if 80% or more of expected doses were recorded by MEMS. Results Overall, 161 patients were enrolled. Median age was 71 years (range, 65 to 89 years); 124 patients (83%) persisted with capecitabine to completion of planned protocol therapy. Adherence was 78% across all cycles, and adherence did not vary by cycle (P = .32). Twenty-five percent of participants took fewer than 80% of expected doses and were nonadherent. In a logistic regression model, participants with node-negative disease (P = .01) and mastectomy (P = .01) were more likely to be nonadherent. Adherence was not related to age, tumor stage, or hormone receptor status. Adherence was not significantly associated with relapse-free survival or grade 3 or 4 toxicity. Conclusion Most older women with early-stage breast cancer were adherent to short-term oral chemotherapy in a randomized clinical trial. Age was not associated with adherence.
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Sargent, Daniel J. , Spriggs, David R. , Baker, Laurence, Rubinstein, Larry , Ratain, Mark J. , Blanc, M , Stewart, David B. , Crowley, John, Groshen, Susan , Humphrey, Jeffrey S., West, Pamela , Berry, Donald A. , Seymour, Lesley , Ivy, S. Percy , Sargent, Daniel J , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | March 10, 2010 | Volume: 16 | Issue: 6 | Pages: 1764-1769

10.1158/1078-0432.ccr-09-3287 | PMID 20215557 Get It

Abstract The optimal design of phase II studies continues to be the subject of vigorous debate, especially studies of newer molecularly targeted agents. The observations that many new therapeutics “fail” in definitive phase III studies, coupled with the numbers of new agents to be tested as well as the increasing costs and complexity of clinical trials, further emphasize the critical importance of robust and efficient phase II design. The Clinical Trial Design Task Force (CTD-TF) of the National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) has published a series of discussion papers on phase II trial design in Clinical Cancer Research. The IDSC has developed formal recommendations about aspects of phase II trial design that are the subject of frequent debate, such as endpoints (response versus progression-free survival), randomization (single-arm designs versus randomization), inclusion of biomarkers, biomarker-based patient enrichment strategies, and statistical design (e.g., two-stage designs versus multiple-group adaptive designs). Although these recommendations in general encourage the use of progression-free survival as the primary endpoint, randomization, inclusion of biomarkers, and incorporation of newer designs, we acknowledge that objective response as an endpoint and single-arm designs remain relevant in certain situations. The design of any clinical trial should always be carefully evaluated and justified based on characteristic specific to the situation. Clin Cancer Res; 16(6); 1764–9
High incidence of profound biotinidase deficiency detected in newborn screening blood spots in the Somalian population in Minnesota
Sarafoglou, Kyriakie , Bentler, Kristi, Gaviglio, A., Redlinger‐Grosse, Krista , Anderson, Carolyn S., McCann, Mark, Bloom, Beth Ann, Babovic‐Vuksanovic, Dusica , Gavrilov, Dimitar , Berry, Susan A. , Gaviglio, Amy , Gaviglio, A.

Mayo Clinic

Journal of Inherited Metabolic Disease | September 14, 2009 | Volume: 32 | Issue: S1 | Pages: 169-173

10.1007/s10545-009-1135-7 | PMID 19757147 Get It

SummaryNewborns identified with profound biotinidase deficiency (BTD) by the Minnesota Newborn Screening Program (MN NBS) between 1 October 2004 and 30 May 2008 were all from new immigrant groups. Thirty‐three positive cases of BTD were identified out of 264 727 infants screened by the Wolf colorimetric system during the period of this study by MN NBS. Five cases of profound BTD (0.1 to <0.6 nmol/min per ml) and 26 cases of partial BTD (0.9 to 2.3 nmol/min per ml) were later confirmed through measurement of serum biotinidase activity. The incidence of combined partial and profound BTD of 1/8540 and that of profound BTD of 1/52 945 in Minnesota are unusually high in comparison with the reported worldwide numbers of 1/61 067 for combined BTD and 1/137 401 for profound BTD. Four out of the 5 cases of profound BTD ascertained in the MN NBS cohort were of Somali ethnic background, and the remaining case was of Asian (Pakistani/Indian) ethnic background. All four Somali patients have the P497S mutation, with one of the four being homozygous for the mutation. The three compound heterozygotes all have a novel mutation (P142T) and two of them have another change (Y428Y) that has never been described. Within the last two decades, Minnesota has become home to an estimated 40 000 Somali immigrants and their children (<1% of the total Minnesota population). New population demographics prompt careful analysis of case cohorts to identify specific groups at risk for rare inborn errors of metabolism.
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Moinpour, Carol M. , Jiang, Caroline S. , Ankerst, Donna P. , Petrylak, Daniel P. , Vinson, Lynne V., Lara, Primo N. , Jones, Sharon, Taplin, Mary Ellen, Burch, Patrick A. , Hussain, Maha , Crawford, E. David , Berry, Donna Lynn , Hussain, Maha H A

Mayo Clinic

Journal of Clinical Oncology | June 16, 2006 | Volume: 24 | Issue: 18 | Pages: 2828-2835

10.1200/jco.2005.04.8207 | PMID 16782921 Get It

Purpose Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP). While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms. Methods Pain palliation and global quality of life (QOL) were the two primary patient-reported outcomes. Pain was measured with the Present Pain Intensity scale of the McGill Pain Questionnaire-Short Form. The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire C30 (QLQ-C30) and its Prostate Cancer Module (PR25) measured QOL and symptom status. Pain and analgesic use were measured at random assignment, every cycle for eight cycles, and 1 year from random assignment; the QLQ-C30 and the PR25 were administered at random assignment, before cycle four (week 10) and cycle eight (month 6) and at 1 year. In addition to the primary intent-to-treat, missing at random analysis, sensitivity analyses were performed to assess robustness of global QOL conclusions under alternative informative missing data assumptions. Results Six hundred seventy four eligible patients received DE (n = 338) or MP (n = 336). In an intention-to-treat analysis, median overall survival was 17.5 months for the DE arm and 15.6 months for the MP arm (P = .02). There were no statistically significant differences in pain palliation between the treatment arms. The sensitivity analyses showed a consistent lack of statistically significant global QOL differences for the two arms. Conclusion DE had superior clinical efficacy (overall survival, time-to-progression, and prostate-specific antigen declines) with similar global QOL and pain palliation in the MP arm.
Duplication of 7p: Further delineation of the phenotype and restriction of the critical region to the distal part of the short arm
Berry, Susan A. , Dewald, Gordon W., King, Richard A. , Reish, Orit

Mayo Clinic

American Journal of Medical Genetics | October 20, 2004 | Volume: 61 | Issue: 1 | Pages: 21-25

10.1002/(sici)1096-8628(19960102)61:1<21::aid-ajmg4>3.0.co;2-# | PMID 8741912 Get It

Prospective Diagnosis of 2-Methylbutyryl-CoA Dehydrogenase Deficiency in the Hmong Population by Newborn Screening Using Tandem Mass Spectrometry
Matern, Dietrich , He, Miao , Berry, Susan A. , Rinaldo, Piero, Whitley, Chester B. , Madsen, P. P., Calcar, Sandra C. Van, Lussky, Richard C., Andresen, Brage Storstein , Wolff, Jon A., Vockley, Jerry

Mayo Clinic

Pediatrics | August 14, 2004 | Volume: 112 | Issue: 1 | Pages: 74-78

10.1542/peds.112.1.74 | PMID 12837870 Get It

Objective. 2-Methylbutyryl-CoA dehydrogenase deficiency, also known as short/branched-chain acyl-CoA dehydrogenase (SBCAD) deficiency, is a recently described autosomal recessive disorder of l-isoleucine metabolism. Only 4 affected individuals in 2 families have been described. One patient developed athetoid cerebral palsy, and another had severe motor developmental delay with muscle atrophy. A sibling of the first patient is asymptomatic after prenatal diagnosis and early treatment. Family investigations in the second family revealed that the patient’s mother was also affected but asymptomatic. Methods. We report 8 additional patients identified by prospective newborn screening using tandem mass spectrometry. Results. Molecular genetic analysis performed for 3 of these patients revealed that all are homozygous for an 1165A&gt;G mutation that causes skipping of exon 10 of the SBCAD gene. Although there was no obvious consanguinity, all patients belong to the Hmong, an ancient ethnic group that originated in China and constitutes only 0.8% and 0.6% of the Minnesota and Wisconsin population, respectively. Dietary treatment was initiated in the neonatal period. Except for 1 patient who developed mild muscle hypotonia, all patients remain asymptomatic at ages ranging from 3 to 14 months of age. Conclusions. These cases suggest that SBCAD deficiency is another inborn error of metabolism detectable by newborn screening using tandem mass spectrometry. The continued efficacy of long-term dietary therapy instituted presymptomatically remains to be established.
Risk Factors for Clinically Relevant Pulmonary Embolism and Deep Venous Thrombosis in Patients Undergoing Primary Hip or Knee Arthroplasty
Mantilla, Carlos B. , Horlocker, Terese T. , Schroeder, Darrell R. , Berry, Daniel J. , Brown, David , Mantilla, Carlos B , Berry, Daniel J , Schroeder, Darrell

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 99 | Issue: 3 | Pages: 552-560

10.1097/00000542-200309000-00009 | PMID 12960538 Get It

Background Prevention of thromboembolic complications after elective lower extremity arthroplasty has increasingly relied on routine thromboprophylaxis in all patients. Not all patients are at equal risk, however, and prophylaxis is not devoid of complications. The aim of this study was to examine the risk factors for clinically relevant pulmonary embolism and deep venous thrombosis after elective primary hip or knee arthroplasty in a large patient population. Methods During the 10-yr study period, 116 of 9,791 patients undergoing primary hip or knee arthroplasty at the authors' institution who experienced pulmonary embolism or deep venous thrombosis within 30 days of surgery were matched at a 1:1 ratio with patients undergoing the same surgery with the same surgeon who did not experience an adverse event. Medical records were reviewed, with data abstracted using a standardized data collection form. Results Increased body mass index (P = 0.031; odds ratio = 1.5 for each 5-kg/m2 increase) and American Society of Anesthesiologists physical status classification of 3 or greater (P = 0.005; odds ratio = 2.6) were found to independently increase the likelihood of pulmonary embolism or deep venous thrombosis. In addition, use of antithrombotic prophylaxis was found to decrease the likelihood of these thromboembolic events (P = 0.050; odds ratio = 0.2 for aspirin or subcutaneous heparin, and odds ratio = 0.4 for warfarin or low-molecular-weight heparin). Conclusions In patients undergoing primary elective lower extremity arthroplasty, obesity, poor American Society of Anesthesiologists physical status classification, and lack of thromboprophylaxis are independent risk factors for clinically relevant thromboembolic events.
Frequency of Myocardial Infarction, Pulmonary Embolism, Deep Venous Thrombosis, and Death following Primary Hip or Knee Arthroplasty
Wood, Margaret, Mantilla, Carlos B. , Horlocker, Terese T. , Schroeder, Darrell R. , Brown, David , Berry, Daniel J. , Mantilla, Carlos B , Schroeder, Darrell

Mayo Clinic

Anesthesiology | November 10, 2003 | Volume: 96 | Issue: 5 | Pages: 1140-1146

10.1097/00000542-200205000-00017 | PMID 11981154 Get It

Background There is limited information about the frequency of perioperative complications after elective primary orthopedic total hip and knee arthroplasty in contemporary practice. The purpose of this study was to determine the frequency of clinically relevant myocardial infarction, pulmonary embolism, deep venous thrombosis, and death within 30 days after elective primary hip or knee arthroplasty treated according to contemporary perioperative management. Methods The authors examined the medical records of consecutive patients undergoing hip or knee arthroplasty at their institution in a 10-yr period. Prospectively collected databases were used to identify patients with the diagnosis of myocardial infarction, pulmonary embolism, deep venous thrombosis, or death using strict validation criteria and diagnostic-certainty categories. Results A total of 10,244 patients underwent primary total hip or knee arthroplasty in the period of study. Of these, 224 patients had one or more adverse events (overall event rate: 2.2%; myocardial infarction: 0.4%; pulmonary embolism: 0.7%; deep venous thrombosis: 1.5%; death: 0.5%). Most adverse events (myocardial infarction, pulmonary embolism, and death) increased in frequency with older age, particularly for patients aged 70 yr or older. Myocardial infarction occurred more frequently in male patients. There were no differences in the overall event frequency between types of procedure. However, pulmonary embolism was highest in patients undergoing bilateral knee operations. Conclusions The overall frequency of serious complications within 30 days after primary total hip or knee arthroplasty with contemporary practice was 2.2%. Accurate knowledge of the perioperative risks associated with widely performed elective operations can be used to implement management strategies that may further improve patient outcomes and decrease cost.
A Tissue-Engineered Stent for Cell-Based Vascular Gene Transfer
Panetta, Carmelo , Miyauchi, Katsumi , Simari, Robert D., Holmes, David R. , Schwartz, Robert S., Caplice, Noel M. , Berry, David

Mayo Clinic

Human Gene Therapy | July 26, 2002 | Volume: 13 | Issue: 3 | Pages: 433-441

10.1089/10430340252792567 | PMID 11860710 Get It